WO2002060880A1 - Derives d'acyclonucleosides pyrimidiniques, leur procede de preparation et leur utilisation - Google Patents
Derives d'acyclonucleosides pyrimidiniques, leur procede de preparation et leur utilisation Download PDFInfo
- Publication number
- WO2002060880A1 WO2002060880A1 PCT/EP2002/000839 EP0200839W WO02060880A1 WO 2002060880 A1 WO2002060880 A1 WO 2002060880A1 EP 0200839 W EP0200839 W EP 0200839W WO 02060880 A1 WO02060880 A1 WO 02060880A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- formula
- compound according
- defined above
- Prior art date
Links
- 0 CC*(C)(*C)C(N(C)COCN(C(Cc1cc(*2)cc(*)c1)=C2C(N1)=O)C1=O)=O Chemical compound CC*(C)(*C)C(N(C)COCN(C(Cc1cc(*2)cc(*)c1)=C2C(N1)=O)C1=O)=O 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
Definitions
- the present invention relates to pyrimidine acyclonucleoside derivatives active as non-nucleoside inhibitors of HIV-1 reverse transcriptase, their preparation process and their use.
- the polytherapies recommended therefore include one or two nucleoside inhibitors with which one or two non-nucleoside inhibitors are associated [G. J. Moyle, Infect. Med. 17 (6) 442-455 (2000)].
- the ⁇ / -hydroxyureido group could therefore constitute an interesting candidate for contracting new bonds with the allosteric site of reverse transcriptase and possibly outside of it with nucleobases of the nucleic acids "treated" by the enzyme.
- the ⁇ / -hydroxyureido group could also prove to be a good candidate because a structure-activity study of acyclonucleosides active against HIV-1 had shown that a hydrophilic group fixed in N-1 on the nucleobase was to decrease the cytotoxicity of the compound [J. M. J. Tronchet, M. Grigorov, N. Dolatshahi, F. Moriaud & J. Weber, Eur. J. Med. Chem., 32, 279-299 (1997)].
- the present invention has been made on the basis of these results.
- R 1 represents an ethyl group or an isopropyl group
- each of the groups R 2 represents, independently of one another, a hydrogen atom, a C 1 -C 3 alkyl group or a halogen atom
- R 3 and R 4 represents a hydrogen atom while the other of the groups R 3 and R 4 represents a group -OH or -OR 5 , where R 5 may be a C 2 acyl group -C 7 , an alkyl group (CrC ⁇ Jaminocarbonyl, an aralkyl group (CrC 6 ) aminocarbonyl optionally substituted on the aryl, an optionally substituted arylcarbonyl group or a heteroarylaminocarbonyl group, or a pharmaceutically acceptable salt thereof.
- R 5 may be a C 2 acyl group -C 7 , an alkyl group (CrC ⁇ Jaminocarbonyl, an aralkyl group (CrC 6 ) aminocarbonyl optionally substituted on the aryl, an optionally substituted arylcarbonyl group or a heteroarylaminocarbonyl group, or a pharmaceutically acceptable salt thereof.
- Another subject of the present invention is: - a compound of Formula I as defined above for use as a medicament;
- the Figure represents antivirograms of three acyclonucleosides produced on two antiviral markers, namely reverse transcriptase and P24, to evaluate the antiretroviral activity of these three acyclonucleosides on HIV-1 lai.
- n 3
- the group R 1 can be either an ethyl group or an isopropyl group, but preferably the group R 1 is an isopropyl group.
- the groups R 2 may each be independently of one another a hydrogen atom, a C 1 -C 3 alkyl group, for example methyl, ethyl, n-propyl or isopropyl, or an atom halogen, for example chlorine, bromine, iodine or fluorine.
- the groups R 2 are identical and they each represent a methyl group.
- One of the groups R 3 and R 4 represents a hydrogen atom while the other of the groups R 3 and R 4 represents a group -OH or a group -OR 5 , where R 5 is a protective group of the group- hydroxy.
- the group R 4 is a hydrogen atom; and when the group R 3 is a hydrogen atom, the group R 4 is a group -OH or a group -OR 5 .
- the group R 3 is a group -OH or a group -OR 5 and that the group R 4 is a hydrogen atom.
- the group R 5 must be chosen from the hydroxy protection groups which can be easily released into a biological medium and which are non-toxic.
- the group R 5 is thus chosen from a C 2 -C 7 acyl group > an alkyl group (C 1 -C 6 ) aminocarbonyl, an aralkyl group (CC 6 ) aminocarbonyl optionally substituted on the aryl, a group optionally substituted arylcarbonyl or a heteroarylaminocarbonyl group, it being understood that the acyl group and the alkyl group of the (C 1 -C 6 ) alkyl aminocarbonyl and aralkyl (C 1 -C 6 ) aminocarbonyl groups may or may not be branched.
- Examples of the C 2 -C acyl group include an acetyl group, a propionyl group, a butyryl group or a pivaloyl group, but are not limited to them.
- Examples of the (C1-C ⁇ ) alkyl aminocarbonyl group include a methylaminocarbonyl group, an ethylaminocarbonyl group, a propylaminocarbonyl group, an isopropylaminocarbonyl group, a butylaminocarbonyl group, a pentylaminocarbonyl group or a hexylaminocarbonyl group, without being limited thereto.
- Examples of the aralkyl (C1-C6) aminocarbonyl group optionally substituted on the aryl include a benzylaminocarbonyl group, a phenethylaminocarbonyl group, a phenyl-3-propylaminocarbonyl group, a phenyl-4-butylaminocarbonyl group, a phenyl-5-pentylaminocarbonyl group or a phenyl-6-hexylaminocarbonyl group, as well as the aralkyl (CC 6 ) - aminocarbonyl groups above in which the aryl carries 1 or 2 selected substituents among halogens, for example chlorine, bromine, fluorine or iodine, C 1 -C 3 alkyls, for example methyl, ethyl, propyl or isopropyl and C ⁇ -C 3l alkoxy groups by for example methoxy, ethoxy, propoxy or isopropoxy, without
- Examples of the optionally substituted arylcarbonyl group include a benzoyl group, a p-chlorobenzoyl group, a p-methoxybenzoyl group or a p-nitrobenzoyl group, without being limited thereto.
- heteroarylaminocarbonyl group examples include an isoxazol-3-ylaminocarbonyl group, an isoxazol-4-ylaminocarbonyl group, an isoxazol-5-ylaminocarbonyl group, a pyridin-2-ylaminocarbonyl group or a pyridine-3-ylaminocarbonyl group, without being limited to them.
- These compounds of Formula I of the present invention may be in the form of conventional pharmaceutically acceptable salts thereof.
- the compounds of the present invention can be prepared according to the following reaction schemes in which n, R 1 , R 2 , R 3 , R 4 and R 5 have the same meanings as those defined above.
- Reaction Scheme 1 shows the steps of the process for preparing the compound of Formula I of the present invention in which R 3 is a group -OH or a group -OR 5 and R 4 is a hydrogen atom:
- nucleobases represented by Formulas V and VI above are known and they are usually prepared by electrophilic substitution [cf., p. ex. YS Lee & YH Kim, Synth. Gommun. 29 (9) 1503-17 (1999)].
- the pyrimidine ring of the modified nucleobases of Formulas V and VI was constructed by condensation according to the principle of the technique described in SM Hannick & Y. Kishi, J. Org. Chem., 48, 3833-3835 (1983), which gives access to a wide variety of bases differing in the nature of the groups R 1 and R 2 .
- the first step of the process consists in reacting a phenylethanenitrile of Formula II with a compound of Formula III, in the presence of Zn in an appropriate solvent, for example an ether such as tetrahydrofuran, at a temperature suitable, for example at reflux, then treating the mixture obtained with an acid, for example hydrochloric acid, to obtain the compound of Formula IV.
- an appropriate solvent for example an ether such as tetrahydrofuran
- this compound of Formula IV is reacted with thiourea in a basic alcoholic medium, for example in a sodium / ethanol (Na / EtOH) medium, at an appropriate temperature, for example at reflux , to obtain the thiouracil of Formula V.
- a basic alcoholic medium for example in a sodium / ethanol (Na / EtOH) medium
- the thiouracil of Formula V is then transformed in a step c) into uracil of Formula VI by treatment with an appropriate dilute organic acid, for example 10% chloroacetic acid.
- fixation of the chain on N 1 of the nucleobase of Formula VI is carried out in a step d) by a conventional glycosidation reaction with a compound of
- n is equal to 3, for example in the presence of hexamethyldisilazane (HMDS), chlorotrimethylsilane (TMSCI) and tin tetrachloride (SnCI) followed by a solvolysis of the ester obtained, for example in a methanol / triethylamine medium (MeOH / Et 3 N), to provide the alcohol of Formula IX.
- HMDS hexamethyldisilazane
- TMSCI chlorotrimethylsilane
- SnCI tin tetrachloride
- the alcohol of Formula IX is then subjected to a Mitsunobu reaction to replace its group -OH with a nitrogen group which will lead to the ⁇ / -hydroxyureido group.
- a Mitsunobu reaction to replace its group -OH with a nitrogen group which will lead to the ⁇ / -hydroxyureido group.
- the treatment of the alcohol of Formula IX under the conditions of a conventional Mitsunobu reaction using ⁇ /, Oj / s (phenoxycarbonyl) hydroxylamine as nucleophile provides the compound of Formula X which, after aminolysis conventional (step f), for example with ammonia or an amide in an appropriate solvent, leads to the compound of Formula la of the present invention which carries a ⁇ / 1 -hydroxyureido terminal group, namely a compound of the present invention of Formula I in which R 3 represents a group -OH and R 4 represents a hydrogen atom.
- the compound of Formula la can then be transformed by an O-acylation or O-carbamylation reaction (step g) into a compound of the present invention of Formula Ib, namely a compound of the present invention of Formula I in which R 3 represents a group -OR 5 and R 4 represents a hydrogen atom, as follows.
- the compound of Formula la of the present invention can be subjected to a conventional O-acylation reaction, for example with a conventional acylating agent of general formula X-CO-R 6 (where R 6 is a C 1 -C 6 alkyl group which may be branched or not, or an optionally substituted aryl group, X possibly being for example a halogen atom or a group R 6 COO-, without X being limited to these), to yield the monoacylated compound of Formula Ib of the present invention in which
- R 5 is a C 2 -C 7 acyl group or an optionally substituted arylcarbonyl group, more lipophilic than its precursor la and in which the N-OH group is protected against oxidation.
- the compound of Formula la of the present invention can also be subjected to a conventional O-carbamylation reaction, for example with a conventional carbamylating agent of general formula X-CO-NH-R 7 (where R 7 is an alkyl group in Ci-C ⁇ which may or may not be branched, an aralkyl group in Ci-Ce optionally substituted on the aryl and in which the alkyl group may be branched or not, or a heteroaryl group, X may for example be a halogen atom , without X being limited thereto) to lead to the compound of the present invention of
- R 5 is an alkyl (C 1 -C 6) aminocarbonyl group, an aralkyl group (C 1 -C 6) aminocarbonyl optionally substituted on the aryl, or a group heteroarylaminocarbonyl, more lipophilic than its precursor la and in which the N-OH group is protected against oxidation.
- step h The alcohol of Formula IX obtained as in steps a) to d) described above with reference to Reaction Scheme 1 is subjected, in step h), to a conventional Mitsunobu reaction using phthalimide as nucleophile, followed by '' a conventional hydrazinolysis to lead to the amine of Formula XI.
- this amine of Formula XI is treated in a conventional manner with a carbonyl donor agent, for example carbonyldiimidazole or phosgene, and O-tertiobutyldimethylsilylhydroxylamine provides the compound of Formula XII.
- a carbonyl donor agent for example carbonyldiimidazole or phosgene
- O-tertiobutyldimethylsilylhydroxylamine provides the compound of Formula XII.
- This compound of Formula XII is then subjected to a de-O-silylation reaction (step j), for example in an acid medium or in the presence of SiO 2 , to provide the compound of the present invention of Formula carrying a ⁇ / 3 -hydroxy fateido terminal group, namely the compound of the present invention of Formula I in which R 3 is a hydrogen atom and R 4 is a group -OH.
- the compound of Formula le of the present invention can then be transformed by an O-acylation or O-carbamylation reaction (step k) into a compound of the present invention of Formula Id, namely a compound of the present invention of Formula I in which R 3 represents a hydrogen atom and R 4 represents a group -OR 5 , as follows.
- the compound of Formula le of the present invention can be subjected to a conventional O-acylation reaction, for example with a conventional acylating agent of general formula X-CO-R 6 (where R 6 is a C1-C6 alkyl group branched or not, or an optionally substituted aryl group, X possibly being for example a halogen atom or an R 6 COO- group, without X being limited to these) to yield the monoacylated compound of Formula Id of the present invention in which R 5 is a C 2 -C 7 acyl group or an optionally substituted arylcarbonyl group.
- a conventional acylating agent of general formula X-CO-R 6 where R 6 is a C1-C6 alkyl group branched or not, or an optionally substituted aryl group, X possibly being for example a halogen atom or an R 6 COO- group, without X being limited to these
- the compound of Formula le of the present invention can also be subjected to a conventional O-carbamylation reaction, for example with a conventional carbamylating agent of general formula X-CO-NH-R 7 (where R 7 is an alkyl group in Ci-Ce, branched or not, a C ⁇ CQ aralkyl group optionally substituted on the aryl and in which the alkyl group can be branched or not, or a heteroaryl group, X can for example be a halogen, without X being limited to these) to lead to the compound of the present invention of Formula Id in which R 5 is an alkyl group (C 1 -C 6 ) v aminocarbonyl, an aralkyl group (in C ⁇ -C 6 ) optionally substituted aminocarbonyl on the aryl, or a heteroarylaminocarbonyl group, more lipophilic than its precursor and in which the N-OH group is protected against oxidation.
- the compounds of the present invention can further be conventionally transformed into pharmaceutically acceptable salts thereof.
- the purpose of the screening is to evaluate the antiretroviral activity of the compounds of the present invention and of the comparative compounds on the HIV-1 lai strain cultivated on peripheral blood mononuclear cells (CMSP).
- CMSP peripheral blood mononuclear cells
- test compounds were incubated for seven days (duration of the anti-HIV test) with the PBMCs in the exponential growth phase.
- RT Reverse Transcriptase
- IMMUNOGENETICS Innotest HIV Antigen mAb Screening kit
- the concentrations of the test compound making it possible to inhibit viral replication by 50 and 90% have been determined. These are the inhibition concentrations Cl 50 and Cl 90 respectively .
- IT 5 o (CC 50 / CI 50 ).
- CMSP were isolated as described in Ulmer et al., Immunobiology, 166 (3), 238-250 (1984) from a healthy donor by a Ficoll gradient (Nicomed
- the PBMCs were activated by phytohemagglutinin for three days and then cultured in a 96-well plate, in base medium (RPMI) supplemented with recombinant human interleukin-2.
- RPMI base medium
- the cells were maintained at 37 ° C., in an atmosphere saturated with humidity, and under 5% CO 2 .
- the PBMCs were pretreated for one hour in the presence of the test compounds at different concentrations, then infected with 100 TCID 50 of HIV-1-Lai [S. Wain-Hobson et al., Science 17, 252 (5008): 961-965 (1991)].
- RT Reverse Transcriptase activity in the culture supernatants by means of the RetroSys kit (Innovagen).
- the RT contained in the supernatant synthesizes, in the presence of bromodeoxyuridine triphosphate (BrdUTP), a strand of DNA complementary to a template fixed to the bottom of the wells of a 96-well plate.
- BrdUTP bromodeoxyuridine triphosphate
- the incorporation of BrdU is quantified by the binding of an anti-BrdU antibody conjugated to alkaline phosphatase.
- the activity of the Bound alkaline phosphatase measured by colorimetry, is proportional to the activity of RT in the culture supernatant.
- the P24 of the supernatants binds to polyclonal anti-HIV antibodies attached to the bottom of the wells of a 96-well plate.
- a biotinylated anti-P24 secondary antibody binds to P24.
- biotin fixes streptavidin, the activity of which, measured by colorimetry, is proportional to the amount of P24 present in the culture supernatant.
- the present invention therefore provides a new type of acyclonucleosides as an antiviral agent, in particular acting as a non-nucleoside inhibitor of HIV-1 reverse transcriptase, which is non-toxic, and which can be active at picomolar or even femtomolar concentrations.
- the compound of the present invention or a pharmaceutically acceptable salt thereof can be used as an active ingredient in a pharmaceutical composition, and it can be used either alone or in admixture with other active ingredients, especially in a composition pharmaceutical intended for use as a medicament in the context of a combination therapy.
- the present invention therefore also provides a pharmaceutical composition containing as active ingredient at least one compound of the present invention or a pharmaceutically acceptable salt thereof.
- the amount of the compound of the present invention or of its pharmaceutically acceptable salt contained in the composition will depend in particular on the weight, the age and the condition of the patient as well as on the effectiveness of the compound.
- the pharmaceutical composition of the present invention may be in a form which can be administered orally or systemically, and it may contain any suitable pharmaceutically acceptable carrier or excipient.
- the compound of the present invention contained in the pharmaceutical composition may advantageously be a compound in which R 3 or R 4 is a group -OR 5 .
- the compound of the present invention is a "prodrug" which, after administration, will be transformed in the body into the compound of the present invention in which R 3 or R 4 is a group -OH.
- Such a compound where R 3 or R 4 is a group -OR 5 may in particular be advantageously used in a delay formula.
- R 5 is an acyl group
- R 5 is particularly advantageous since it is more lipophilic than its precursor and the N-OH group is protected against oxidation.
- it can be deacylated in the blood at rates controllable by the nature of the acyl group.
- branched R 5 groups such as for example the pivaloyl group
- the present invention it has been possible to improve the binding to the receptor, namely the allosteric site of HIV-1 reverse transcriptase, which is manifested by a lower inhibitory concentration, which implies better selectivity. , a lower preparation cost and a lower propensity to select resistant mutants.
- acyclonucleosides with a ⁇ / -hydroxyureido group of the present invention can be detected by Electronic Paramagnetic Resonance (EPR) after oxidation to corresponding aminoxylated free radicals. Oxidation in air, possibly facilitated by low UV irradiation, leads to a very low stationary concentration of paramagnetic species which, given the high sensitivity and high selectivity of the RPE technique, makes it possible to follow the molecule in complex biological media.
- EPR Electronic Paramagnetic Resonance
- Toxicity tests of Compounds 3 and 5 of the present invention were also carried out on bone marrow cells according to the following procedure.
- Balb / c mouse bone marrow cells were cultured at 5 x 10 5 cells / ml in 1 ml cultures in RPMl 1640 medium supplemented with 1 mM glutamine, 10% fetal calf serum, penicillin and streptomycin (GIBCO, USA)
- the cells were stimulated by adding 1 ng / ml of Srem cell factor (c-kit ligand), IL3 and GM-CSF (Pharmingen, USA) in the presence of increasing concentrations of Compounds 3 and 5 of the present invention ranging from 1 x 10 "12 to 1 x 10- 5 M.
- Srem cell factor c-kit ligand
- IL3 IL3
- GM-CSF GM-CSF
- the differentiation of the cells was evaluated by flow cytometry (Facs-Calibur, BECTON DICKINSON, USA) by double labeling of the cells with anti-CD38 antibodies coupled with phycoerythrin (PE), anti-Gr1 coupled with fluorescein 5 (FI ), anti GM-PE and anti CD11 b-FI (Pharmingen, USA).
- PE phycoerythrin
- FI fluorescein 5
- GM-PE anti GM-PE
- CD11 b-FI CD11 b-FI
- the cell proliferation was identical to that observed in the absence of Compound 3 or 5 of the present invention.
- the starting materials, the reagents and the solvents used in the following syntheses are all commercial products originating from Fluka (Buchs,
- the 6-dimethylbenzyl-5-isopropyl-2-thiouracil obtained was dissolved in a 10% aqueous solution of chloroacetic acid (200 ml) and the solution was maintained at reflux for 24 h then cooled to room temperature and the precipitate obtained was separated by filtration and washed with cold ethanol then ether, then vacuum dried at 40 ° C to provide 6- (3,5-dimethylbenzyl) -5-isopropyluracil (7 g,
- reaction medium was then extracted with dichloromethane (50 ml) and the organic phase was washed with water (10 ml) then with a saturated solution of sodium chloride (10 ml) and dried (sulfate of sodium).
- the organic phase was then concentrated and subjected to "flash" chromatography on a column of silica gel (dichloromethane / methanol 9: 1) to provide 70 mg (75%) of 1- (3- / V 1 -acetoxyureidopropyloxymethyl) -6- (3,5-dimethylbenzyl) -5-isopropyluracil desired in the form of a solid. Melting point: 77 - 79 ° C.
- the aqueous phase was extracted with dichloromethane (3 ⁇ 10 ml) and the organic phases, combined, washed with an aqueous solution of sodium hydrogencarbonate (10 ml), a saturated aqueous solution of sodium chloride (10 ml), dried (sodium sulfate) left by distillation of the solvent 180 mg of 1- (3-A / 1 -pivaloyloxyureidopropyloxymethyl) -6- (3,5-dimethylbenzyl) - 5-isopropyluracil which was subjected to "flash" chromatography on a column of silica gel (dichloromethane / methanol 24: 1) to provide 127 mg (78%) of the 1- (3- ⁇ / 1 -pivaIoyloxy negligenceidopropyloxyméthyl) -6- (3,5-dimethylbenzyl) -5- isopropyluracil as a solid. Melting point 132-133 ° C
- reaction medium was then concentrated and subjected to “flash” chromatography on a silica gel column (dichloromethane / methanol 49: 1) and the product obtained was purified by a new “flash” chromatography on a silica gel column ( ethyl acetate / petroleum ether 1: 1) to provide 5-ethyl- 6- (3,5-dimethylbenzyl) -1- (3-phthalimidopropyloxy-methyl) uracil (0.23 g, 79%).
- reaction medium was then reduced to 20 C C, concentrated, and subjected to a gel chromatography column of silica (ethyl acetate / ether 1: 9) then to a chromatography on a "flash" column of silica gel (methanol / chloroform 3:97) to yield 250 mg of intermediate compound 6- (3,5-dimethylbenzyl ) -1 - [3- ( ⁇ / -phenoxycarbonyl- / V- phenoxycarbonyloxyamino) propyloxymethyl] -5-ethyluracil.
- 5-ethyluracil desired (40 mg, 24%) in the form of a viscous oil which spontaneously crystallizes in a few hours at 20 ° C.
- the concentrated reaction medium subjected to chromatography on a "flash" column of silica gel (dichloromethane / methanol 19: 1) provided an oil which, taken up in ether, provided the 1 - (2-V 1 -hydroxyureidoethoxymethyl) - 6- (3,5-dimethylbenzyl) -5-ethyl-uracil (36.6 mg, 36%) in the form of a white solid. Melting point: 147 - 148 ° CR F 0.18 (dichloromethane / methanol 9: 1)
- Benzoyl chloride (1 ml) was added slowly at 0 ° C to a solution of 1,4-butanediol (18 ml, 0.2 mmol) in pyridine (16 ml) , 0.1 mmol). After 4 hours of stirring at 0 ° C., the reaction medium was concentrated and the pyridine was removed by co-distillation with toluene.
- reaction mixture was then brought to 20 ° C., concentrated and subjected to chromatography on a column of silica gel (ethyl acetate / ethyl ether 1: 9), then to chromatography on a "flash" column (methanol / chloroform 3:97) to yield 260 mg of the intermediate compound 6- (3,5-dimethylbenzyl) -1- [4- (V- phenoxycarbonyl- ⁇ / -phenoxycarbonyloxyamino) butyloxymethyl] -5-ethyluracil
- This intermediate compound was immediately dissolved in a methanolic solution saturated with ammonia (5 ml) and the reaction medium stirred at 20 ° C for 24 h. By this time, the intermediate compound had fully reacted (thin layer chromatography) and the reaction medium, concentrated, was subjected to chromatography on a “flash” column on silica gel (methanol / ethyl acetate 1: 9) to provide 1- (4- / V 1 -hydroxyureaidobutyloxymethyl) -6- (3,5-dimethylbenzyl) -5-ethyluracil (45 mg, 23%) in the form of a solid. Melting point: 148-150 ° C,
- reaction medium was stirred for 4 h at 20 ° C., concentrated, then subjected to chromatography on a “flash” column of silica gel (dichloromethane / ethanol 9: 1) to provide, after recrystallization (ethyl acetate / methanol) 1- (2- ⁇ / 1 -hydroxyureidoethoxymethyl) -6-benzyI-5-ethyluracil (80 mg, 45%). Melting point: 276-277 ° C, R F 0.25 (dichloromethane / methane 9: 1).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60221794T DE60221794D1 (de) | 2001-01-29 | 2002-01-25 | Pyrimidinische azyklonukleoside, verfahren zur ihrer herstellung und ihre verwendung |
US10/470,564 US6911450B1 (en) | 2001-01-29 | 2002-01-25 | Pyrimidine acyclonucleoside derivatives, preparation method and use thereof |
CA002436958A CA2436958A1 (fr) | 2001-01-29 | 2002-01-25 | Derives d'acyclonucleosides pyrimidiniques, leur procede de preparation et leur utilisation |
EP02703583A EP1355887B1 (fr) | 2001-01-29 | 2002-01-25 | Derives d'acyclonucleosides pyrimidiniques, leur procede de preparation et leur utilisation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/01165 | 2001-01-29 | ||
FR0101165A FR2820135B1 (fr) | 2001-01-29 | 2001-01-29 | Derives d'acyclonucleosides pyrimidiniques, leur procede de preparation et leur utilisation |
FR01/08052 | 2001-06-19 | ||
FR0108052A FR2826006A1 (fr) | 2001-06-19 | 2001-06-19 | Derive d'acyclonucleoside pyrimidinique, son procede de preparation et son utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002060880A1 true WO2002060880A1 (fr) | 2002-08-08 |
Family
ID=26212851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/000839 WO2002060880A1 (fr) | 2001-01-29 | 2002-01-25 | Derives d'acyclonucleosides pyrimidiniques, leur procede de preparation et leur utilisation |
Country Status (7)
Country | Link |
---|---|
US (1) | US6911450B1 (fr) |
EP (1) | EP1355887B1 (fr) |
CN (1) | CN1231472C (fr) |
AT (1) | ATE370127T1 (fr) |
CA (1) | CA2436958A1 (fr) |
DE (1) | DE60221794D1 (fr) |
WO (1) | WO2002060880A1 (fr) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7713687B2 (en) | 2000-11-29 | 2010-05-11 | Xy, Inc. | System to separate frozen-thawed spermatozoa into x-chromosome bearing and y-chromosome bearing populations |
US7723116B2 (en) | 2003-05-15 | 2010-05-25 | Xy, Inc. | Apparatus, methods and processes for sorting particles and for providing sex-sorted animal sperm |
US7758811B2 (en) | 2003-03-28 | 2010-07-20 | Inguran, Llc | System for analyzing particles using multiple flow cytometry units |
US7820425B2 (en) | 1999-11-24 | 2010-10-26 | Xy, Llc | Method of cryopreserving selected sperm cells |
US7833147B2 (en) | 2004-07-22 | 2010-11-16 | Inguran, LLC. | Process for enriching a population of sperm cells |
US7838210B2 (en) | 2004-03-29 | 2010-11-23 | Inguran, LLC. | Sperm suspensions for sorting into X or Y chromosome-bearing enriched populations |
US7855078B2 (en) | 2002-08-15 | 2010-12-21 | Xy, Llc | High resolution flow cytometer |
US7929137B2 (en) | 1997-01-31 | 2011-04-19 | Xy, Llc | Optical apparatus |
US8137967B2 (en) | 2000-11-29 | 2012-03-20 | Xy, Llc | In-vitro fertilization systems with spermatozoa separated into X-chromosome and Y-chromosome bearing populations |
US8486618B2 (en) | 2002-08-01 | 2013-07-16 | Xy, Llc | Heterogeneous inseminate system |
US8497063B2 (en) | 2002-08-01 | 2013-07-30 | Xy, Llc | Sex selected equine embryo production system |
US9365822B2 (en) | 1997-12-31 | 2016-06-14 | Xy, Llc | System and method for sorting cells |
US11230695B2 (en) | 2002-09-13 | 2022-01-25 | Xy, Llc | Sperm cell processing and preservation systems |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8354421B2 (en) * | 2007-06-29 | 2013-01-15 | Korea Research Insitute Of Chemical Technology | HIV reverse transcriptase inhibitors |
MX2009013804A (es) * | 2007-06-29 | 2010-02-03 | Korea Res Inst Chem Tech | Inhibidores novedosos de transcriptasa inversa de vih. |
WO2009085797A1 (fr) * | 2007-12-21 | 2009-07-09 | Gilead Sciences, Inc. | Procédés de préparation d'inhibiteurs de la transcriptase inverse du vih |
EP2725029A1 (fr) | 2012-10-29 | 2014-04-30 | Laboratoire Biodim | Nouveaux composés antibactériens et leurs applications biologiques |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0420763A2 (fr) * | 1989-09-29 | 1991-04-03 | Mitsubishi Chemical Corporation | Dérivés de nucléosides d'acyclopyrimidines 6-substituées et agent antiviral les contenant comme ingrédients actifs |
EP0631783A1 (fr) * | 1993-06-03 | 1995-01-04 | Mitsubishi Chemical Corporation | Combinaisons antivirales de 2',3'-didéoxy-ribonucléosides avec des dérivés 5-substitués du 6-benzyl-1-éthoxyméthyl-uracile |
-
2002
- 2002-01-25 AT AT02703583T patent/ATE370127T1/de not_active IP Right Cessation
- 2002-01-25 CA CA002436958A patent/CA2436958A1/fr not_active Abandoned
- 2002-01-25 WO PCT/EP2002/000839 patent/WO2002060880A1/fr active IP Right Grant
- 2002-01-25 CN CNB02805458XA patent/CN1231472C/zh not_active Expired - Fee Related
- 2002-01-25 EP EP02703583A patent/EP1355887B1/fr not_active Expired - Lifetime
- 2002-01-25 US US10/470,564 patent/US6911450B1/en not_active Expired - Fee Related
- 2002-01-25 DE DE60221794T patent/DE60221794D1/de not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0420763A2 (fr) * | 1989-09-29 | 1991-04-03 | Mitsubishi Chemical Corporation | Dérivés de nucléosides d'acyclopyrimidines 6-substituées et agent antiviral les contenant comme ingrédients actifs |
EP0631783A1 (fr) * | 1993-06-03 | 1995-01-04 | Mitsubishi Chemical Corporation | Combinaisons antivirales de 2',3'-didéoxy-ribonucléosides avec des dérivés 5-substitués du 6-benzyl-1-éthoxyméthyl-uracile |
Non-Patent Citations (6)
Title |
---|
CARBOHYDR. LETT. (1997), 2(5), 313-320 * |
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TRONCHET, JEAN M. J. ET AL: "Antiviral nucleoside N-hydroxyureas and carbamates", XP002172470, retrieved from STN Database accession no. 127:346601 * |
JALALI-HERAVI, M. ET AL: "Use of Artificial Neural Networks in a QSAR Study of Anti-HIV Activity for a Large Group of HEPT Derivatives", J. CHEM. INF. COMPUT. SCI. ( 2000 ), 40(1), 147 -154, XP002172469 * |
LUCO, JUAN M. ET AL: "QSAR Based on Multiple Linear Regression and PLS Methods for the Anti-HIV Activity of a Large Group of HEPT Derivatives", J. CHEM. INF. COMPUT. SCI. ( 1997 ), 37(2), 392 -401, XP002172468 * |
PONTIKIS, RENEE ET AL: "Synthesis and Anti-HIV Activity of Novel N-1 Side Chain-Modified Analogs of 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT)", J. MED. CHEM. ( 1997 ), 40(12), 1845 -1854, XP002172467 * |
TRONCHET JMJ GRIGOROV M DOLATSHAHI N MORIAUD F WEBER J: "A QSAR study confirming the heterogeneity of the HEPT derivative series regarding their interaction with HIV reverse transcriptase", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.CHIMICA THERAPEUTICA,FR,EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, vol. 32, no. 4, 1997, pages 279 - 299, XP004086652, ISSN: 0223-5234 * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7929137B2 (en) | 1997-01-31 | 2011-04-19 | Xy, Llc | Optical apparatus |
US9422523B2 (en) | 1997-12-31 | 2016-08-23 | Xy, Llc | System and method for sorting cells |
US9365822B2 (en) | 1997-12-31 | 2016-06-14 | Xy, Llc | System and method for sorting cells |
US7820425B2 (en) | 1999-11-24 | 2010-10-26 | Xy, Llc | Method of cryopreserving selected sperm cells |
US9879221B2 (en) | 2000-11-29 | 2018-01-30 | Xy, Llc | Method of in-vitro fertilization with spermatozoa separated into X-chromosome and Y-chromosome bearing populations |
US7771921B2 (en) | 2000-11-29 | 2010-08-10 | Xy, Llc | Separation systems of frozen-thawed spermatozoa into X-chromosome bearing and Y-chromosome bearing populations |
US8652769B2 (en) | 2000-11-29 | 2014-02-18 | Xy, Llc | Methods for separating frozen-thawed spermatozoa into X-chromosome bearing and Y-chromosome bearing populations |
US7713687B2 (en) | 2000-11-29 | 2010-05-11 | Xy, Inc. | System to separate frozen-thawed spermatozoa into x-chromosome bearing and y-chromosome bearing populations |
US8137967B2 (en) | 2000-11-29 | 2012-03-20 | Xy, Llc | In-vitro fertilization systems with spermatozoa separated into X-chromosome and Y-chromosome bearing populations |
US8497063B2 (en) | 2002-08-01 | 2013-07-30 | Xy, Llc | Sex selected equine embryo production system |
US8486618B2 (en) | 2002-08-01 | 2013-07-16 | Xy, Llc | Heterogeneous inseminate system |
US7855078B2 (en) | 2002-08-15 | 2010-12-21 | Xy, Llc | High resolution flow cytometer |
US11230695B2 (en) | 2002-09-13 | 2022-01-25 | Xy, Llc | Sperm cell processing and preservation systems |
US11261424B2 (en) | 2002-09-13 | 2022-03-01 | Xy, Llc | Sperm cell processing systems |
US10100278B2 (en) | 2003-03-28 | 2018-10-16 | Inguran, Llc | Multi-channel system and methods for sorting particles |
US7799569B2 (en) | 2003-03-28 | 2010-09-21 | Inguran, Llc | Process for evaluating staining conditions of cells for sorting |
US8664006B2 (en) | 2003-03-28 | 2014-03-04 | Inguran, Llc | Flow cytometer apparatus and method |
US8709825B2 (en) | 2003-03-28 | 2014-04-29 | Inguran, Llc | Flow cytometer method and apparatus |
US8709817B2 (en) | 2003-03-28 | 2014-04-29 | Inguran, Llc | Systems and methods for sorting particles |
US8748183B2 (en) | 2003-03-28 | 2014-06-10 | Inguran, Llc | Method and apparatus for calibrating a flow cytometer |
US9040304B2 (en) | 2003-03-28 | 2015-05-26 | Inguran, Llc | Multi-channel system and methods for sorting particles |
US11718826B2 (en) | 2003-03-28 | 2023-08-08 | Inguran, Llc | System and method for sorting particles |
US9377390B2 (en) | 2003-03-28 | 2016-06-28 | Inguran, Llc | Apparatus, methods and processes for sorting particles and for providing sex-sorted animal sperm |
US7758811B2 (en) | 2003-03-28 | 2010-07-20 | Inguran, Llc | System for analyzing particles using multiple flow cytometry units |
US7943384B2 (en) | 2003-03-28 | 2011-05-17 | Inguran Llc | Apparatus and methods for sorting particles |
US11104880B2 (en) | 2003-03-28 | 2021-08-31 | Inguran, Llc | Photo-damage system for sorting particles |
US7723116B2 (en) | 2003-05-15 | 2010-05-25 | Xy, Inc. | Apparatus, methods and processes for sorting particles and for providing sex-sorted animal sperm |
US7892725B2 (en) | 2004-03-29 | 2011-02-22 | Inguran, Llc | Process for storing a sperm dispersion |
US7838210B2 (en) | 2004-03-29 | 2010-11-23 | Inguran, LLC. | Sperm suspensions for sorting into X or Y chromosome-bearing enriched populations |
US7833147B2 (en) | 2004-07-22 | 2010-11-16 | Inguran, LLC. | Process for enriching a population of sperm cells |
Also Published As
Publication number | Publication date |
---|---|
ATE370127T1 (de) | 2007-09-15 |
CA2436958A1 (fr) | 2002-08-08 |
US6911450B1 (en) | 2005-06-28 |
CN1231472C (zh) | 2005-12-14 |
DE60221794D1 (de) | 2007-09-27 |
EP1355887B1 (fr) | 2007-08-15 |
EP1355887A1 (fr) | 2003-10-29 |
CN1492859A (zh) | 2004-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1355887B1 (fr) | Derives d'acyclonucleosides pyrimidiniques, leur procede de preparation et leur utilisation | |
EP2891658B1 (fr) | Promédicament du ténofovir et utilisations pharmaceutiques associées | |
FI93217B (fi) | Menetelmä terapeuttisesti aktiivisten nukleosidijohdannaisten estereiden ja amidien valmistamiseksi | |
US7968605B2 (en) | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | |
EP0274453A2 (fr) | Nouveaux composés à activité d'inhibiteurs de collagénase, procédé pour les préparer et compositions pharmaceutiques contenant ces composés | |
EP1369419B1 (fr) | Compose de n-phenylarylsulfonamide, medicament contenant le compose en tant que principe actif, intermediaire pour le compose et ses procedes de production | |
EP2321323B9 (fr) | Derives dimeriques d'artemisinine et application en therapie anticancereuse | |
US20080026984A1 (en) | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | |
EP0532410A1 (fr) | Dérivés hétérocycliques N-substitués, comme inhibiteurs de l'angiotensive II | |
EP1095029B1 (fr) | Derives de la piperazine pour l'inhibition de la replication du virus de l'immunodeficience humaine | |
JP3009196B2 (ja) | 抗ウイルス活性を有する薬剤、燐脂質誘導体及びその製造方法 | |
EP0533827B1 (fr) | Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent | |
WO1989008115A1 (fr) | NOUVEAUX DERIVES DE LA DEOXY-2'-URIDINE SUBSTITUEE EN POSITION 5, 3' ou 5' PAR DES GROUPEMENTS alpha-AMINO ACYLES, PROCEDE POUR LEUR OBTENTION ET MEDICAMENTS LES CONTENANT | |
EP0117771A1 (fr) | Imino-2 pyrrolidines, leur procédé de préparation et leurs applications en thérapeutique | |
FR2613717A1 (fr) | Derives d'acides pyrimidinecarboxyliques, a action therapeutique | |
US7214794B2 (en) | Ceramide analogs, process for their preparation and their use as antitumor agents | |
EP0172083A1 (fr) | Nouveaux amides substitués, leur préparation et les médicaments qui les contiennent | |
FR2499577A1 (fr) | Nouvelles 1-(2-chloroethyl)-1-nitrosourees-3-substituees par un reste de sucre, utiles notamment comme agents antitumoraux et leur procede de preparation | |
EP0772630B1 (fr) | Derives de streptogramine, leur preparation et les compositions pharmaceutiques qui les contiennent | |
LU81554A1 (de) | Alkylthiophenoxyalkylamines | |
JPH0322394B2 (fr) | ||
US8420626B2 (en) | Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof | |
WO1998031688A1 (fr) | Derives d'acides boroniques inhibiteurs d'angiogenese | |
FR2820135A1 (fr) | Derives d'acyclonucleosides pyrimidiniques, leur procede de preparation et leur utilisation | |
FR2826006A1 (fr) | Derive d'acyclonucleoside pyrimidinique, son procede de preparation et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 02805458.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002561030 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2436958 Country of ref document: CA Ref document number: 10470564 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002703583 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002703583 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002703583 Country of ref document: EP |